Compare Ascendis Pharma A/S (ASND) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Costco Wholesale Corporation — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Costco Wholesale Corporation trades at $921.18 (market cap $406.34B). The key difference: Costco Wholesale Corporation is far larger — about 22.9× Ascendis Pharma A/S's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | COST | |
|---|---|---|
Market Cap | $17.74B | $406.34B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $1.09K |
52-Week Low | $163.32 | $849.63 |
Enterprise Value | $18.11B | $394.48B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Costco Wholesale Corporation (COST) trades at $920.73, up 0.49% on the day, with a bearish technical signal but strong fundamentals. The company reported revenue of $275.24 billion in 2025, with net income of $8.10 billion and consistent earnings beats in recent quarters. Recent news highlights membership fee increases and robust March sales growth of 11.3% year-over-year (GlobeNewsWire, 2026-04-08).
Outlook remains positive driven by membership revenue and expansion, though high valuation multiples pose a risk. Analyst consensus is bullish with a $1,120 price target, but technical indicators suggest near-term pressure. Key risks include competitive pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
